These results might be due to: 1) lnc-MALAT1 reduced the production of inflammation cytokines, further decreased inflammation, and attenuated disease progression, thus it led to better RFS in AIS patients (10,20); 2) lnc-MALAT1 might facilitate sensitivity to treatment in AIS, thereby it increased treatment efficacy and resulted in longer RFS in AIS patients. The gene discussed is MALAT1; the disease is androgen insensitivity syndrome.